

DB=PGPB,USPT; PLUR=YES; OP=ADJ

L5 (cd40L or cd40 adj ligand or gp39 or 5c8) same (cd20) same (leukem\$ or lymphoma\$) 13 L5

L4 (cd40L or cd40 adj ligand or gp39 or 5c8) and (cd20) and (leukem\$ or lymphoma\$) 487 L4

L3 L2 and (leukem\$ or lymphoma\$) 17 L3

L2 L1 and (cd40L or cd40 adj ligand or gp39 or 5c8) and (cd20) 17 L2

L1 hanna.in.

---

09/435992

---

**Search Results - Record(s) 1 through 10 of 13 returned.**

- 
- ☐ 1. 20040018522. 06 May 03. 29 Jan 04. Identification of dysregulated genes in patients with multiple sclerosis. Dangond, Fernando, et al. 435/6; 702/20 C12Q001/68 G06F019/00 G01N033/48 G01N033/50.
- 
- ☐ 2. 20040010810. 04 Jun 03. 15 Jan 04. Generation of xenogeneic antibodies. Kucherlapati, Raju, et al. 800/6; 530/388.15 C12P021/08 C07K016/00 A01K067/027.
- 
- ☐ 3. 20040009479. 24 Apr 02. 15 Jan 04. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases. Wohlgemuth, Jay, et al. 435/6; C12Q001/68.
- 
- ☐ 4. 20030219433. 14 Feb 03. 27 Nov 03. Anti-CD20 antibodies and fusion proteins thereof and methods of use. Hansen, Hans, et al. 424/141.1; 530/388.15 A61K039/395 C07K016/44.
- 
- ☐ 5. 20030211107. 12 Sep 02. 13 Nov 03. Use of CD23 antagonists for the treatment of neoplastic disorders. Hariharan, Kandasamy, et al. 424/155.1; 435/7.23 514/12 G01N033/574 A61K039/395 A61K038/17.
- 
- ☐ 6. 20030204090. 13 Mar 03. 30 Oct 03. Indolizine compounds. Ono, Mitsunori, et al. 546/138; C07D455/02.
- 
- ☐ 7. 20030180292. 14 Mar 02. 25 Sep 03. Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy. Hanna, Nabil, et al. 424/141.1; 424/1.49 424/144.1 514/105 514/251 514/263.1 514/34 A61K051/00 A61K039/395 A61K031/525 A61K031/52.
- 
- ☐ 8. 20030103971. 12 Sep 02. 05 Jun 03. Immunoregulatory antibodies and uses thereof. Hariharan, Kandasamy, et al. 424/141.1; 424/155.1 A61K039/395.
- 
- ☐ 9. 20020172677. 03 Apr 01. 21 Nov 02. Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies. Lahn, Michael F., et al. 424/145.1; 424/43 A61K039/395 A61K009/00.
- 
- ☐ 10. 20020028178. 16 May 01. 07 Mar 02. Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/1.49; 424/143.1 A61K039/395 A61K051/00.
- 

**Generate Collection**

**Print**

Term	Documents
CD40L	1406
CD40LS	3
CD40	3448
CD40S	0
LIGAND	72582

LIGANDS	59509
GP39	326
GP39S	0
5C8	112
5C8S	0
CD20	1849
((CD40L OR CD40 ADJ LIGAND OR GP39 OR 5C8) SAME (CD20) SAME (LEUKEM\$ OR LYMPHOMA\$)).PGPB,USPT.	13

There are more results than shown above. [Click here to view the entire set.](#)

[Prev](#)

returned.

---

☐ 11. 20020009444. 25 Apr 01. 24 Jan 02. Intrathecal administration of rituximab for treatment of central nervous system lymphomas. Grillo-Lopez, Antonio J.. 424/142.1; 424/1.49 424/1.65 514/251 514/283 A61K051/10 A61K039/395 A61K051/04 A61K031/525 A61K031/475.

---

☐ 12. 20020006404. 31 Jan 01. 17 Jan 02. Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/142.1; 424/155.1 A61K039/395.

---

☐ 13. 20010018041. 16 Apr 01. 30 Aug 01. Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy. Hanna, Nabil, et al. 424/1.49; 424/181.1 A61K039/395.

---

Generate Collection

Print